Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.

Sorich MJ, Rowland A, Karapetis CS, Hopkins AM.

J Thorac Oncol. 2019 Apr 15. pii: S1556-0864(19)30285-0. doi: 10.1016/j.jtho.2019.04.006. [Epub ahead of print]

PMID:
30999110
2.

Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.

Hopkins AM, Van Dyk M, Rowland A, Sorich MJ.

Pigment Cell Melanoma Res. 2019 Feb 13. doi: 10.1111/pcmr.12773. [Epub ahead of print]

PMID:
30758912
3.

The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms.

Meech R, Hu DG, McKinnon RA, Mubarokah SN, Haines AZ, Nair PC, Rowland A, Mackenzie PI.

Physiol Rev. 2019 Apr 1;99(2):1153-1222. doi: 10.1152/physrev.00058.2017. Review.

PMID:
30724669
4.

Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology.

Sorich MJ, Mutlib F, van Dyk M, Hopkins AM, Polasek TM, Marshall JC, Rodrigues AD, Rowland A.

J Clin Pharmacol. 2019 Jun;59(6):872-879. doi: 10.1002/jcph.1377. Epub 2019 Jan 11.

PMID:
30633368
6.

Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development.

Polasek TM, Rayner CR, Peck RW, Rowland A, Kimko H, Rostami-Hodjegan A.

Clin Pharmacol Drug Dev. 2019 May;8(4):418-425. doi: 10.1002/cpdd.638. Epub 2018 Nov 30.

PMID:
30500115
7.

Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.

Rowland A, Ruanglertboon W, van Dyk M, Wijayakumara D, Wood LS, Meech R, Mackenzie PI, Rodrigues AD, Marshall JC, Sorich MJ.

Br J Clin Pharmacol. 2019 Jan;85(1):216-226. doi: 10.1111/bcp.13793. Epub 2018 Nov 16.

PMID:
30340248
8.

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials.

Hopkins AM, Nguyen AM, Karapetis CS, Rowland A, Sorich MJ.

Cancers (Basel). 2018 Oct 15;10(10). pii: E384. doi: 10.3390/cancers10100384.

9.

Defining significant childhood illness and injury in the Emergency Department: a consensus of UK and Ireland expert opinion.

Lillitos PJ, Lyttle MD, Roland D, Powell CV, Sandell J, Rowland AG, Chapman SM, Maconochie IK; PERUKI and GAPRUKI.

Emerg Med J. 2018 Nov;35(11):685-690. doi: 10.1136/emermed-2018-207802. Epub 2018 Oct 3.

10.

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability.

Hopkins AM, Rowland A, Sorich MJ.

BMC Med. 2018 Sep 28;16(1):165. doi: 10.1186/s12916-018-1154-z.

11.
12.

Rowland et al. Respond.

Rowland AS, Gorman SA, Thoma RJ, Annett RA, McGrew CA, Yeo RA, Mayer AR, King JH, Campbell RA.

Am J Public Health. 2018 Jul;108(7):e12-e13. doi: 10.2105/AJPH.2018.304443. No abstract available.

13.

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.

Rowland A, van Dyk M, Hopkins AM, Mounzer R, Polasek TM, Rostami-Hodjegan A, Sorich MJ.

Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228. doi: 10.1002/cpt.1076. Epub 2018 Apr 19.

PMID:
29574693
14.

Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.

van Dyk M, Marshall JC, Sorich MJ, Wood LS, Rowland A.

Eur J Clin Pharmacol. 2018 Jul;74(7):913-920. doi: 10.1007/s00228-018-2450-4. Epub 2018 Mar 23.

PMID:
29572563
15.

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.

Mangoni AA, Kichenadasse G, Rowland A, Sorich MJ.

Ther Adv Med Oncol. 2018 Feb 5;10:1758834018755090. doi: 10.1177/1758834018755090. eCollection 2018.

16.

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Polasek TM, Tucker GT, Sorich MJ, Wiese MD, Mohan T, Rostami-Hodjegan A, Korprasertthaworn P, Perera V, Rowland A.

Br J Clin Pharmacol. 2018 Mar;84(3):462-476. doi: 10.1111/bcp.13480. Epub 2018 Jan 11.

17.

Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.

Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A.

Br J Clin Pharmacol. 2018 Mar;84(3):501-509. doi: 10.1111/bcp.13478. Epub 2018 Jan 10.

18.

Risk of Concussion During Sports Versus Physical Education Among New Mexico Middle and High School Students.

Campbell RA, Gorman SA, Thoma RJ, Annett RD, McGrew CA, Yeo RA, Mayer AR, King JH, Rowland AS.

Am J Public Health. 2018 Jan;108(1):93-95. doi: 10.2105/AJPH.2017.304107. Epub 2017 Nov 21.

19.

Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin.

Miners JO, Pattanawongsa A, Rowland A.

Br J Clin Pharmacol. 2018 Feb;84(2):392-393. doi: 10.1111/bcp.13443. Epub 2017 Nov 3. No abstract available.

20.

Opposing effects of rheumatoid arthritis and low dose prednisolone on arginine metabolomics.

Radhakutty A, Mangelsdorf BL, Drake SM, Rowland A, Smith MD, Mangoni AA, Thompson CH, Burt MG.

Atherosclerosis. 2017 Nov;266:190-195. doi: 10.1016/j.atherosclerosis.2017.10.004. Epub 2017 Oct 6.

PMID:
29035782

Supplemental Content

Loading ...
Support Center